(Q51636999)
Statements
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors (English)
Branimir I Sikic
Lee S Rosen
Patricia LoRusso
Wen Wee Ma
Jonathan W Goldman
Amy Weise
A Dimitrios Colevas
Salim Yazji
Angela Shen
Stuart Johnston
Hsin-Ju Hsieh
Iris T Chan
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference